Evidence map›Paper›PMID 39119336›Full record

ArticleFrontiers in immunology2024

mRNA lipid nanoparticles expressing cell-surface cleavage independent HIV Env trimers elicit autologous tier-2 neutralizing antibodies.

Javier Guenaga, Mehrdad Alirezaei, Yu Feng, Mohamad-Gabriel Alameh, Wen-Hsin Lee, Sabyasachi Baboo, Jocelyn Cluff, Richard Wilson, Shridhar Bale, Gabriel Ozorowski and 8 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. AnScience immunology · 2025
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Javier Guenaga *Wyatt Lab, Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, United States.
Mehrdad Alirezaei *Wyatt Lab, Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, United States.
Yu FengWyatt Lab, Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, United States.
Mohamad-Gabriel AlamehWeissman Lab, Penn Institute for RNA Innovation, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Wen-Hsin LeeWard Lab, Department of Integrative Structural and Computational Biology, Scripps Research, La Jolla, CA, United States.
Sabyasachi BabooScripps Consortium for HIV/AIDS Vaccine Development (CHAVD), Scripps Research, La Jolla, CA, United States.
Jocelyn CluffWyatt Lab, Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, United States.
Richard WilsonWyatt Lab, Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, United States.
Shridhar BaleWyatt Lab, Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, United States.
Gabriel OzorowskiWard Lab, Department of Integrative Structural and Computational Biology, Scripps Research, La Jolla, CA, United States.
Paulo LinAcuitas Therapeutics, Vancouver, BC, Canada.
Ying TamAcuitas Therapeutics, Vancouver, BC, Canada.
Jolene K DiedrichPaulson Lab, Department of Molecular Medicine, Scripps Research, La Jolla, CA, United States.
John R YatesPaulson Lab, Department of Molecular Medicine, Scripps Research, La Jolla, CA, United States.
James C PaulsonWyatt Lab, Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, United States.
Andrew B WardWard Lab, Department of Integrative Structural and Computational Biology, Scripps Research, La Jolla, CA, United States.
Drew WeissmanWeissman Lab, Penn Institute for RNA Innovation, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Richard T WyattWyatt Lab, Department of Immunology and Microbiology, Scripps Research, La Jolla, CA, United States.

Funding

Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4M
Project 2_NillaP01AI157299 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI WYATT, RICHARD THOMAS · 2021 to 2025
$17.3M
N-glycan baiting to target the highly effective HIV Env shieldR01AI145055 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI WYATT, RICHARD THOMAS · 2019 to 2023
$3.3M
NIAID NIH HHS P01 AI157299NIAID NIH HHS P30 AI036214NIAID NIH HHS R01 AI145055NIAID NIH HHS UM1 AI144462
6 · The paper itself

Abstract

The HIV-1 envelope glycoprotein (Env) is the sole neutralizing determinant on the surface of the virus. The Env gp120 and gp41 subunits mediate receptor binding and membrane fusion and are generated from the gp160 precursor by cellular furins. This cleavage event is required for viral entry. One approach to generate HIV-1 neutralizing antibodies following immunization is to express membrane-bound Env anchored on the cell-surface by genetic means using the natural HIV gp41 transmembrane (TM) spanning domain. To simplify the process of Env trimer membrane expression we sought to remove the need for Env precursor cleavage while maintaining native-like conformation following genetic expression. To accomplish these objectives, we selected our previously developed 'native flexibly linked' (NFL) stabilized soluble trimers that are both near-native in conformation and cleavage-independent. We genetically fused the NFL construct to the HIV TM domain by using a short linker or by restoring the native membrane external proximal region, absent in soluble trimers, to express the full HIV Env ectodomain on the plasma membrane. Both forms of cell-surface NFL trimers, without and with the MPER, displayed favorable antigenic profiles by flow cytometry when expressed from plasmid DNA or mRNA. These results were consistent with the presence of well-ordered cell surface native-like trimeric Env, a necessary requirement to generate neutralizing antibodies by vaccination. Inoculation of rabbits with mRNA lipid nanoparticles (LNP) expressing membrane-bound stabilized HIV Env NFL trimers generated tier 2 neutralizing antibody serum titers in immunized animals. Multiple inoculations of mRNA LNPs generated similar neutralizing antibody titers compared to immunizations of matched NFL soluble proteins in adjuvant. Given the recent success of mRNA vaccines to prevent severe COVID, these are important developments for genetic expression of native-like HIV Env trimers in animals and potentially in humans.

Indexed as

AIDS VaccinesAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusHIV-1HIV AntibodiesNanoparticlesRNA, MessengerAnimalsFemaleHIV InfectionsHumansLipidsLiposomesProtein MultimerizationRabbitsAIDS VaccinesAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusHIV AntibodiesLipid NanoparticlesLipidsLiposomesRNA, MessengerEnvHIVimmunogenicitymRNANFLSOSIPvaccine

Identifiers

PMID39119336
PMCPMC11306127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.